These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 31843957)

  • 21. Anti-PCSK9 antibodies inhibit pro-atherogenic mechanisms in APOE*3Leiden.CETP mice.
    Schuster S; Rubil S; Endres M; Princen HMG; Boeckel JN; Winter K; Werner C; Laufs U
    Sci Rep; 2019 Jul; 9(1):11079. PubMed ID: 31366894
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of alirocumab on individuals with type 2 diabetes, high triglycerides, and low high-density lipoprotein cholesterol.
    Colhoun HM; Leiter LA; Müller-Wieland D; Cariou B; Ray KK; Tinahones FJ; Domenger C; Letierce A; Israel M; Samuel R; Del Prato S
    Cardiovasc Diabetol; 2020 Feb; 19(1):14. PubMed ID: 32035487
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Chlorogenic acid protects against atherosclerosis in ApoE-/- mice and promotes cholesterol efflux from RAW264.7 macrophages.
    Wu C; Luan H; Zhang X; Wang S; Zhang X; Sun X; Guo P
    PLoS One; 2014; 9(9):e95452. PubMed ID: 25187964
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Both transient and continuous corticosterone excess inhibit atherosclerotic plaque formation in APOE*3-leiden.CETP mice.
    Auvinen HE; Wang Y; Princen H; Romijn JA; Havekes LM; Smit JW; Meijer OC; Biermasz NR; Rensen PC; Pereira AM
    PLoS One; 2013; 8(5):e63882. PubMed ID: 23717502
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Factorial Effects of Evolocumab and Atorvastatin on Lipoprotein Metabolism.
    Watts GF; Chan DC; Dent R; Somaratne R; Wasserman SM; Scott R; Burrows S; R Barrett PH
    Circulation; 2017 Jan; 135(4):338-351. PubMed ID: 27941065
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of the PCSK9 antibody alirocumab on coronary atherosclerosis in patients with acute myocardial infarction: a serial, multivessel, intravascular ultrasound, near-infrared spectroscopy and optical coherence tomography imaging study-Rationale and design of the PACMAN-AMI trial.
    Zanchin C; Koskinas KC; Ueki Y; Losdat S; Häner JD; Bär S; Otsuka T; Inderkum A; Jensen MRJ; Lonborg J; Fahrni G; Ondracek AS; Daemen J; van Geuns RJ; Iglesias JF; Matter CM; Spirk D; Juni P; Mach F; Heg D; Engstrom T; Lang I; Windecker S; Räber L
    Am Heart J; 2021 Aug; 238():33-44. PubMed ID: 33951415
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Aliskiren inhibits atherosclerosis development and improves plaque stability in APOE*3Leiden.CETP transgenic mice with or without treatment with atorvastatin.
    Kühnast S; van der Hoorn JW; van den Hoek AM; Havekes LM; Liau G; Jukema JW; Princen HM
    J Hypertens; 2012 Jan; 30(1):107-16. PubMed ID: 22134386
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Acyl-CoA:cholesterol acyltransferase inhibitor avasimibe reduces atherosclerosis in addition to its cholesterol-lowering effect in ApoE*3-Leiden mice.
    Delsing DJ; Offerman EH; van Duyvenvoorde W; van Der Boom H; de Wit EC; Gijbels MJ; van Der Laarse A; Jukema JW; Havekes LM; Princen HM
    Circulation; 2001 Apr; 103(13):1778-86. PubMed ID: 11282910
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Co-administration of CSL112 (apolipoprotein A-I [human]) with atorvastatin and alirocumab is not associated with increased hepatotoxic or toxicokinetic effects in rats.
    Beyerle A; Greene B; Dietrich B; Kingwell BA; Panjwani P; Wright SD; Herzog E
    Toxicol Appl Pharmacol; 2021 Jul; 422():115557. PubMed ID: 33932462
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy of alirocumab for reducing plaque vulnerability: Study protocol for ALTAIR, a randomized controlled trial in Japanese patients with coronary artery disease receiving rosuvastatin.
    Otake H; Sugizaki Y; Toba T; Nagano Y; Tsukiyama Y; Yanaka KI; Yamamoto H; Nagasawa A; Onishi H; Takeshige R; Nakano S; Matsuoka Y; Tanimura K; Kawamori H; Shinke T; Hirata KI
    J Cardiol; 2019 Mar; 73(3):228-232. PubMed ID: 30579806
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and Safety of Alirocumab in High-Risk Patients With Clinical Atherosclerotic Cardiovascular Disease and/or Heterozygous Familial Hypercholesterolemia (from 5 Placebo-Controlled ODYSSEY Trials).
    McCullough PA; Ballantyne CM; Sanganalmath SK; Langslet G; Baum SJ; Shah PK; Koren A; Mandel J; Davidson MH
    Am J Cardiol; 2018 Apr; 121(8):940-948. PubMed ID: 29472008
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of alirocumab on coronary atheroma volume in Japanese patients with acute coronary syndromes and hypercholesterolemia not adequately controlled with statins: ODYSSEY J-IVUS rationale and design.
    Ako J; Hibi K; Kozuma K; Miyauchi K; Morino Y; Shinke T; Tsujita K; Uno K; Kawabata Y; Hiro T
    J Cardiol; 2018 Jun; 71(6):583-589. PubMed ID: 29606415
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Simultaneous intake of oat bran and atorvastatin reduces their efficacy to lower lipid levels and atherosclerosis in LDLr-/- mice.
    Eussen SR; Rompelberg CJ; Andersson KE; Klungel OH; Hellstrand P; Oste R; van Kranen H; Garssen J
    Pharmacol Res; 2011 Jul; 64(1):36-43. PubMed ID: 21371558
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cholesterol-independent effects of atorvastatin prevent cardiovascular morbidity and mortality in a mouse model of atherosclerotic plaque rupture.
    Roth L; Rombouts M; Schrijvers DM; Martinet W; De Meyer GR
    Vascul Pharmacol; 2016 May; 80():50-8. PubMed ID: 26826559
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Design and rationale of the ODYSSEY DM-DYSLIPIDEMIA trial: lipid-lowering efficacy and safety of alirocumab in individuals with type 2 diabetes and mixed dyslipidaemia at high cardiovascular risk.
    Müller-Wieland D; Leiter LA; Cariou B; Letierce A; Colhoun HM; Del Prato S; Henry RR; Tinahones FJ; Aurand L; Maroni J; Ray KK; Bujas-Bobanovic M
    Cardiovasc Diabetol; 2017 May; 16(1):70. PubMed ID: 28545518
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A novel mouse model of familial combined hyperlipidemia and atherosclerosis.
    Chen MJ; Xu YT; Sun L; Wang ZH; Little PJ; Wang L; Xian XD; Weng JP; Xu SW
    Acta Pharmacol Sin; 2024 Jun; 45(6):1316-1320. PubMed ID: 38459255
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy.
    McKenney JM; Koren MJ; Kereiakes DJ; Hanotin C; Ferrand AC; Stein EA
    J Am Coll Cardiol; 2012 Jun; 59(25):2344-53. PubMed ID: 22463922
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Atorvastatin inhibits the atherosclerotic lesion induced by tumor necrosis factor-like weak inducer of apoptosis in apolipoprotein E deficient mice].
    Fernández-Laso V; Sastre C; Egido J; Martín-Ventura JL; Blanco-Colio LM
    Clin Investig Arterioscler; 2015; 27(1):17-25. PubMed ID: 25027757
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and safety of alirocumab in patients with or without prior coronary revascularization: Pooled analysis of eight ODYSSEY phase 3 trials.
    Kereiakes DJ; Lepor NE; Gerber R; Veronica Lee L; Elassal J; Thompson D; Michael Gibson C
    Atherosclerosis; 2018 Oct; 277():211-218. PubMed ID: 30025648
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Statin administration or blocking PCSK9 alleviates airway hyperresponsiveness and lung fibrosis in high-fat diet-induced obese mice.
    Liang L; Chung SI; Guon TE; Park KH; Lee JH; Park JW
    Respir Res; 2024 May; 25(1):213. PubMed ID: 38762465
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.